isoniazid and sq 109
isoniazid has been researched along with sq 109 in 11 studies
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Govender, K; Govender, P; Govender, T; Kruger, HG; Maguire, GE; Muthusamy, K; Onajole, OK; Pillay, M; van Helden, PD; Wiid, I | 1 |
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
| Biava, M; Cocozza, M; Consalvi, S; Poce, G | 1 |
| Bhakta, S; Brown, AK; Castagnolo, D; Dasugari, S; Evangelopoulos, D; Maitra, A; Manetti, F; McHugh, TD; Mortazavi, PN; Petricci, E; Scalacci, N; Twist, A | 1 |
| Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM | 1 |
| Coward, L; Gorman, GS; Jia, L; Noker, PE; Tomaszewski, JE | 1 |
| Chen, P; Einck, L; Gearhart, J; Nacy, CA; Protopopova, M | 1 |
| Zhang, Y | 1 |
| Cole, ST; Hartkoorn, RC; Lechartier, B | 1 |
| Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS | 1 |
| Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS | 1 |
Reviews
5 review(s) available for isoniazid and sq 109
| Article | Year |
|---|---|
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis | 2022 |
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
Development of new drug-regimens against multidrug-resistant tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant | 2019 |
Trials
1 trial(s) available for isoniazid and sq 109
| Article | Year |
|---|---|
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary | 2017 |
Other Studies
5 other study(ies) available for isoniazid and sq 109
| Article | Year |
|---|---|
Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents.
Topics: Alkanes; Animals; Antitubercular Agents; Cattle; Cell Line; Cell Survival; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Prenylation | 2009 |
Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercul
Topics: Adamantane; Antitubercular Agents; Carrier Proteins; Cell Line; Cell Survival; Computational Biology; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium; Mycobacterium tuberculosis; Pharmaceutical Preparations; Piperazines; Pyrroles; Structure-Activity Relationship | 2016 |
Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.
Topics: Adamantane; Amino Acid Sequence; Antitubercular Agents; Databases, Genetic; Electrophoresis, Polyacrylamide Gel; Ethambutol; Ethylenediamines; Isoniazid; Molecular Sequence Data; Mycobacterium tuberculosis; Peptide Fragments; Peptide Mapping; Protein Hydrolysates; Proteome; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Trypsin | 2005 |
Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
Topics: Adamantane; Antitubercular Agents; Drug Resistance, Bacterial; Drug Synergism; Ethylenediamines; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin | 2006 |
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins | 2012 |